Treatment with the anti-interleukin-23p19 inhibitor mirikizumab led to significant improvements in patient-assessed disease severity and activity, as well as abdominal pain, in individuals with moderate-to-severe active Crohn’s disease, according to phase II data presented at the Crohn’s and Colitis Congress (CCC) 2022.
Digital health technologies (DHTs) can help lower healthcare utilization and costs but appear to have not enough juice to reduce the risk of relapse, improve quality of life (QoL), and increase treatment adherence in patients with inflammatory bowel disease (IBD), according to a study.
The benefits of the 5:2 diet – which involves limited caloric intake (500–600 kcal) for 2 nonconsecutive days per week only – mirrored those achieved with a multicomponent weight management advice, according to a UK study on adults with obesity. However, the benefits eventually waned, even when intensified with group support.
The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.
New drug applications approved by US FDA as of 16-31 December 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Bifidobacterium adolescentis, a unique gut bacterium, is correlated with the efficacy of the inactivated and mRNA coronavirus disease 2019 (COVID-19) vaccines available in Hong Kong, a collaborative study between the Chinese University of Hong Kong (CUHK) and the University of Hong Kong (HKU) has shown.
A post hoc analysis of the phase III True North study showed that the benefits of ozanimod on clinical remission and response in patients with moderate-to-severe ulcerative colitis (UC) as seen in the global analysis were consistent in the analysis of the North American cohort.
Sleeve gastrectomy was associated with a lower risk of mortality and complications over 5 years compared with gastric bypass, although the former intervention comes with an increased risk of surgical revision, reveals a recent study on patients undergoing bariatric surgery for weight loss.